Evaluation of the Effect of Foeniculum vulgare on the Expression of E-Cadherin, Dysadherin and Ki-67 in BALB/C Mice with 4T1 Model of Breast Cancer

References

• Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, Chen VW, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417–35. doi:10.1007/s10552-008-9256-0
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Meng X, Gan R-Y, Zhang J-J, Li H-B. Dietary natural products for prevention and treatment of breast cancer. Nutrients. 2017;9(7):728. doi:10.3390/nu9070728
   PubMed Web of Science ®Google Scholar
• Mitra S, Dash R. Natural products for the management and prevention of breast cancer. Evid Based Complement Alternat Med. 2018;2018:8324696. doi:10.1155/2018/8324696
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95(26):15665–70. doi:10.1073/pnas.95.26.15665
   PubMed Web of Science ®Google Scholar
• Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9(1):1–6.
   PubMedGoogle Scholar
• Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340(22):1733–9. doi:10.1056/NEJM199906033402206
   PubMed Web of Science ®Google Scholar
• Henderson JW, Donatelle RJ. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Alternat Therap Health Med. 2004;10:52–57.
   PubMed Web of Science ®Google Scholar
• Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter a qualitative study in women with breast cancer. J Fam Pract. 1999;48(6):453.
   PubMed Web of Science ®Google Scholar
• Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431–441. doi:10.1016/j.lfs.2005.09.012
   PubMed Web of Science ®Google Scholar
• Garzoli S, Božović M, Baldisserotto A, Sabatino M, Cesa S, Pepi F, Vicentini CB, Manfredini S, Ragno R. Essential oil extraction, chemical analysis and anti-Candida activity of Foeniculum vulgare Miller – new approaches. Nat Prod Res. 2018;32(11):1254–1259. doi:10.1080/14786419.2017.1340291
   PubMed Web of Science ®Google Scholar
• Lall N, Kishore N, Binneman B, Twilley D, van de Venter M, Du Plessis-Stoman D, Boukes G, Hussein A. Cytotoxicity of syringin and 4-methoxycinnamyl alcohol isolated from Foeniculum vulgare on selected human cell lines. Nat Prod Res. 2015;29(18):1752–1756. doi:10.1080/14786419.2014.999058
   PubMed Web of Science ®Google Scholar
• Arantes S, Piçarra A, Candeias F, Caldeira AT, Martins MR, Teixeira D. Antioxidant activity and cholinesterase inhibition studies of four flavouring herbs from Alentejo. Nat Prod Res. 2017;31(18):2183–2187. doi:10.1080/14786419.2017.1278598
   PubMed Web of Science ®Google Scholar
• Božović M, Navarra A, Garzoli S, Pepi F, Ragno R. Essential oils extraction: a 24-hour steam distillation systematic methodology. Nat Prod Res. 2017;31(20):2387–2396. doi:10.1080/14786419.2017.1309534
   PubMed Web of Science ®Google Scholar
• Kheirandish S, Homaee F. Ki-67 protein: a proliferation index in breast cancer. Rev Clin Med. 2015;2:205–208.
   Google Scholar
• Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–552. doi:10.1007/s10549-013-2560-8
   PubMed Web of Science ®Google Scholar
• Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237–252. doi:10.1146/annurev.bi.59.070190.001321
   PubMed Web of Science ®Google Scholar
• Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011;3(5):227–233. doi:10.4297/najms.2011.3227
   PubMedGoogle Scholar
• Bracke M, Van Roy F, Mareel M. The E-cadherin/catenin complex in invasion and metastasis. Attempts to understand metastasis formation I. Curr Top Microbiol Immunol. 1996;213(Pt 1):123–161.
   Google Scholar
• Larue L, Ohsugi M, Hirchenhain J, Kemler R. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci USA. 1994;91(17):8263–8267. doi:10.1073/pnas.91.17.8263
   PubMed Web of Science ®Google Scholar
• Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113(1):173–185. doi:10.1083/jcb.113.1.173
   PubMed Web of Science ®Google Scholar
• Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J. 1995;14(24):6107–6115.
   PubMed Web of Science ®Google Scholar
• Vleminckx K, Vakaet L, JrMareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66(1):107–119. doi:10.1016/0092-8674(91)90143-M
   PubMed Web of Science ®Google Scholar
• Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA. 2002;99(1):365–370. doi:10.1073/pnas.012425299
   PubMed Web of Science ®Google Scholar
• Nam J-S, Hirohashi S, Wakefield LM. Dysadherin: a new player in cancer progression. Cancer Lett. 2007;255(2):161–169. doi:10.1016/j.canlet.2007.02.018
   PubMed Web of Science ®Google Scholar
• Daaboul HE, Dagher C, Taleb RI, Bodman-Smith K, Shebaby WN, El-Sibai M, Mroueh MA, Daher CF. β-2-Himachalen-6-ol inhibits 4T1 cells-induced metastatic triple negative breast carcinoma in murine model. Chem Biol Interact. 2019;309:108703. doi:10.1016/j.cbi.2019.06.016
   PubMed Web of Science ®Google Scholar
• Ramroodi N, Khani M, Ganjali Z, Javan MR, Sanadgol N, Khalseh R, Ravan H, Sanadgol E, Abdollahi M. Prophylactic effect of BIO-1211 small-molecule antagonist of VLA-4 in the EAE mouse model of multiple sclerosis. Immunol Invest. 2015;44(7):694–712. doi:10.3109/08820139.2015.1085391
   PubMed Web of Science ®Google Scholar
• Sarvandi SS, Joghataei MT, Parivar K, Khosravi M, Sarveazad A, Sanadgol N. In vitro differentiation of rat mesenchymal stem cells to hepatocyte lineage. Iran J Basic Med Sci. 2015;18(1):89–97.
   PubMed Web of Science ®Google Scholar
• Sanadgol N, Mostafaie A, Bahrami G, Mansouri K, Ghanbari F, Bidmeshkipour A. Elaidic acid sustains LPS and TNF-alpha induced ICAM-1 and VCAM-I expression on human bone marrow endothelial cells (HBMEC). Clin Biochem. 2010;43(12):968–72. doi:10.1016/j.clinbiochem.2010.04.066
   PubMed Web of Science ®Google Scholar
• Badgujar SB, Patel VV, Bandivdekar AH: Foeniculum vulgare Mill: a review of its botany, phytochemistry, pharmacology, contemporary application, and toxicology. BioMed Res Int. 2014.
   Google Scholar
• Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670–3695. doi:10.1016/j.bbagen.2013.02.008
   PubMed Web of Science ®Google Scholar
• Syed FQ, Elkady AI, Mohammed FA, Mirza MB, Hakeem KR, Alkarim S. Chloroform fraction of Foeniculum vulgare induced ROS mediated, mitochondria-caspase-dependent apoptotic pathway in MCF-7, human breast cancer cell line. J Ethnopharmacol. 2018;218:16–26. doi:10.1016/j.jep.2018.02.029
   PubMed Web of Science ®Google Scholar
• Choo EJ, Rhee Y-H, Jeong S-J, Lee H-J, Kim HS, Ko HS, Kim J-H, Kwon T-R, Jung JH, Kim JH, et al. Anethole exerts antimetatstaic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull. 2011;34(1):41–46. doi:10.1248/bpb.34.41
   PubMed Web of Science ®Google Scholar
• Nam JH, Lee D-U. Foeniculum vulgare extract and its constituent, trans-anethole, inhibit UV-induced melanogenesis via ORAI1 channel inhibition. J Dermatol Sci. 2016;84(3):305–313. doi:10.1016/j.jdermsci.2016.09.017
   PubMed Web of Science ®Google Scholar
• Arunkumar D, Mohandass S. Effect of Foeniculum vulgare on melanogenesis in B16 melanoma cells. J Chem Pharm Res. 2015;7:249–252.
   Google Scholar
• Cabral C, Miranda M, Gonçalves MJ, Cavaleiro C, Cruz MT, Salgueiro L. Assessment of safe bioactive doses of Foeniculum vulgare Mill. essential oil from Portugal. Nat Prod Res. 2017;31(22):2654–2659. doi:10.1080/14786419.2017.1292266
   PubMed Web of Science ®Google Scholar
• Akhbari M, Kord R, Jafari Nodooshan S, Hamedi S. Analysis and evaluation of the antimicrobial and anticancer activities of the essential oil isolated from Foeniculum vulgare from Hamedan, Iran. Nat Prod Res. 2019;33(11). doi:10.1080/14786419.2017.1423310
   PubMed Web of Science ®Google Scholar
• Ko F-N, Liao C-H, Kuo Y-H, Lin Y-L. Antioxidant properties of demethyldiisoeugenol. Biochim Biophys Acta. 1995;1258(2):145–152. doi:10.1016/0005-2760(95)00111-o
   PubMedGoogle Scholar
• Rajakumar D, Rao M. Dehydrozingerone and isoeugenol as inhibitors of lipid peroxidation and as free radical scavengers. Biochem Pharmacol. 1993;46(11):2067–2072. doi:10.1016/0006-2952(93)90649-h
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Suzuki T. Cytotoxic and xenoestrogenic effects via biotransformation of trans-anethole on isolated rat hepatocytes and cultured MCF-7 human breast cancer cells. Biochem Pharmacol. 2003;66(1):63–73. doi:10.1016/s0006-2952(03)00208-9
   PubMed Web of Science ®Google Scholar
• Rhee Y-H, Chung P-S, Kim S-H, Ahn JC. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2014;447(4):557–562. doi:10.1016/j.bbrc.2014.01.121
   PubMed Web of Science ®Google Scholar
• Lubet RA, Steele VE, Eto I, Juliana MM, Kelloff GJ, Grubbs CJ. Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Int J Cancer. 1997;72(1):95–101. doi:10.1002/(sici)1097-0215(19970703)72:1<95::aid-ijc14>3.0.co;2-9
   PubMed Web of Science ®Google Scholar
• Chen C, De Gasperi M, Salcedo R, Cavazos D, deGraffenried L. Evaluation of the phytochemical anethole as an anti-tumor agent in MCF-7 cells. AACR, 2009.
   Google Scholar
• Chen CH, deGraffenried LA. Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status. Phytomedicine. 2012;19(8/9):763–767. doi:10.1016/j.phymed.2012.02.017
   PubMed Web of Science ®Google Scholar
• Carvalho AA, Andrade LN, de Sousa ÉBV, de Sousa DP. Antitumor phenylpropanoids found in essential oils. Biomed Res Int. 2015;2015:392674. doi:10.1155/2015/392674
   PubMed Web of Science ®Google Scholar
• Al-Harbi M, Qureshi S, Raza M, Ahmed M, Giangreco A, et al. Influence of anethole treatment on the tumour induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice. Eur J Cancer Prevent: 1995;4:307–318.:
   PubMed Web of Science ®Google Scholar
• Jana S, Patra K, Mukherjee G, Bhattacharjee S, Mandal DP. Antitumor potential of anethole singly and in combination with cyclophosphamide in murine Sarcoma-180 transplantable tumor model. RSC Adv. 2015;5(70):56549–56559. doi:10.1039/C5RA07230A
   Web of Science ®Google Scholar
• Wiirzler L, Silva-Comar FS, Silva-Filho S, Oliveira M, Bersani-Amado C, et al. Evaluation of immunomodulatory activity of trans-anethole and estragole, and protective effect against cyclophosphamide-induced suppression of immunity in Swiss albino mice. Int J Appl Res Nat Prod. 2015;8:26–33.:
   Google Scholar
• Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw. 1996;7(2):93–124.
   PubMed Web of Science ®Google Scholar
• Robertson FM, Ross MS, Tober KL, Long BW, Oberyszyn TM. Inhibitation of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. Carcinogenesis. 1996;17(8):1719–1728. doi:10.1093/carcin/17.8.1719
   PubMed Web of Science ®Google Scholar
• Suganuma M, Okabe S, Sueoka E, Iida N, Komori A, Kim SJ, Fujiki H. A new process of cancer prevention mediated through inhibition of tumor necrosis factor α expression. Cancer Res. 1996;56(16):3711–3715.
   PubMed Web of Science ®Google Scholar
• Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer. 2007;96(9):1404–1408. doi:10.1038/sj.bjc.6603743
   PubMed Web of Science ®Google Scholar
• Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008;3(2):107–110. doi:10.1097/JTO.0b013e3181630ece
   PubMed Web of Science ®Google Scholar
• Murray P, Frampton G, Nelson P. Cell adhesion molecules: sticky moments in the clinic. BMJ. 1999;319:332. doi:10.1136/bmj.319.7206.332
   Google Scholar
• Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D. Cell-cell adhesion and communication. In: Molecular cell biology. 4th ed. New York: WH Freeman, 2000.
   Google Scholar
• Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–634. doi:10.1038/nrm1699
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428. doi:10.1172/JCI39104
   PubMed Web of Science ®Google Scholar
• Rakha E, Abd El Rehim D, Pinder S, Lewis S, Ellis I, E. ‐ E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46(6):685–693. doi:10.1111/j.1365-2559.2005.02156.x
   PubMed Web of Science ®Google Scholar
• Rothberg BEG, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat. 2006;100(2):139–148. doi:10.1007/s10549-006-9248-2
   PubMed Web of Science ®Google Scholar
• Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Michele C, Tuccari G, Adamo V, et al. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget. 2017;8(44):76974–76986. doi:10.18632/oncotarget.20293
   PubMedGoogle Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–454. doi:10.1038/nrc822
   PubMed Web of Science ®Google Scholar
• Beavon I. Regulation of E-cadherin: does hypoxia initiate the metastatic cascade?. MP, Mol Pathol. 1999;52(4):179–188. doi:10.1136/mp.52.4.179
   PubMedGoogle Scholar
• Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K, Hirakawa K. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103(2):249–255. doi:10.1038/sj.bjc.6605735
   PubMed Web of Science ®Google Scholar
• Shen T, Zhang K, Siegal GP, Wei S. Prognostic value of E-cadherin and β-catenin in triple-negative breast cancer. Am J Clin Pathol. 2016;146(5):603–610. doi:10.1093/ajcp/aqw183
   PubMed Web of Science ®Google Scholar
• Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer. 2003;88(5):726–732. doi:10.1038/sj.bjc.6600778
   PubMed Web of Science ®Google Scholar
• Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(9):4407–4412. doi:10.1210/jc.2002-021757
   PubMed Web of Science ®Google Scholar
• Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, Sekihara H, Hirohashi S. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol. 2003;21(4):659–667. doi:10.1200/JCO.2003.06.179
   PubMed Web of Science ®Google Scholar
• Shimada Y, Hashimoto Y, Kan T, Kawamura J-i, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, et al. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology. 2004;67(1):73–80. doi:10.1159/000080289
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Appl Immunohistochem Mol Morphol. 2004;12(4):323–328. doi:10.1097/00129039-200412000-00006
   PubMedGoogle Scholar
• Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res. 2004;10(4):212–218. doi:10.1007/bf03033763
   PubMed Web of Science ®Google Scholar
• Batistatou A, Scopa CD, Ravazoula P, Nakanishi Y, Peschos D, Agnantis NJ, Hirohashi S, Charalabopoulos KA. Involvement of dysadherin and E-cadherin in the development of testicular tumours. Br J Cancer. 2005;93(12):1382–1387. doi:10.1038/sj.bjc.6602880
   PubMed Web of Science ®Google Scholar
• Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch. 2006;448(6):763–767. doi:10.1007/s00428-006-0183-8
   PubMed Web of Science ®Google Scholar
• Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2005;103(8):1693–1700. doi:10.1002/cncr.20984
   Google Scholar
• Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y, Hirohashi S, Charalabopoulos K. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. Am J Surg Pathol. 2006;30(2):185–193. doi:10.1097/01.pas.0000178090.54147.f8
   PubMed Web of Science ®Google Scholar
• Nam J-S, Kang M-J, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 2006;66(14):7176–7184. doi:10.1158/0008-5472.CAN-06-0825
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–7220. doi:10.1200/JCO.2005.07.501
   PubMed Web of Science ®Google Scholar
• Petit T, Wilt M, Velten M, Millon R, Rodier J-F, Borel C, Mors R, Haegelé P, Eber M, Ghnassia J-P, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205–211. doi:10.1016/s0959-8049(03)00675-0
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32. doi:10.1002/cncr.22381
   PubMed Web of Science ®Google Scholar
• Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116(1):53–68. doi:10.1007/s10549-008-0081-7
   PubMed Web of Science ®Google Scholar
• Grazziotin LR, Dada BR, de la Rosa Jaimes C, Cheung WY, Marshall DA. Chromogenic and silver in situ hybridization for identification of her 2 overexpression in breast cancer patients: a systematic review and meta-analysis. Appl Immunohistochem Molec Morphol. 2019;1:31135445. doi:10.1097/PAI.0000000000000773
   Google Scholar
• Goddard KAB, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genom. 2012;15(1):1–10. doi:10.1159/000325746
   PubMed Web of Science ®Google Scholar
• Ha B, Ko H, Kim B, Sohn EJ, Jung JH, Kim JS, Yoon JJ, Won G, Kim J-H, Jung D-b, et al. Regulation of crosstalk between epithelial to mesenchymal transition molecules and MMP-9 mediates the antimetastatic activity of anethole in DU145 prostate cancer cells. J Nat Prod. 2014;77(1):63–69. doi:10.1021/np4006376
   PubMed Web of Science ®Google Scholar
• Sánchez-Tilló E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A, Postigo A, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69(20):3429–3456. doi:10.1007/s00018-012-1122-2
   PubMed Web of Science ®Google Scholar
• Jiang R, Li Y, Xu Y, Zhou Y, Pang Y, Shen L, Zhao Y, Zhang J, Zhou J, Wang X, et al. EMT and CSC-like properties mediated by the IKKβ/IκBα/RelA signal pathway via the transcriptional regulator, snail, are involved in the arsenite-induced neoplastic transformation of human keratinocytes. Arch Toxicol. 2013;87(6):991–1000. doi:10.1007/s00204-012-0933-0
   PubMed Web of Science ®Google Scholar